PANDEMIC PROVIDER WEEKLY BROWN BAG

Updated January 2023

Updates

COVID-19 Vaccine Presentations Available to Order in ASIIS Job Aid

***NEW* Pediatric Pfizer-BioNTech Bivalent (Ages 6 months - 4 years) - Maroon Cap**

100-dose minimum order

- 10-dose multi-dose vial
- NDC 59267-0609-02

***NEW* Moderna Bivalent Booster (Ages 6 months - 5 years) - Dark Pink Cap with Yellow Border on label**

100-dose minimum order

- 2-dose multi-dose vial
- NDC 80777-0283-99

***NEW* Pfizer-BioNTech (Ages 12+, No Diluent) - Gray Cap is No Longer Available to Order in ASIIS**

***NEW* Novavax is No Longer Available to Order in ASIIS**

ADHS Vaccine Reference Sheets - Pfizer-BioNTech

NEW **Pediatric Pfizer Monovalent & Bivalent (Ages 6mo - 4 years) - Maroon Cap**

- PEDIATRIC Pfizer Vaccine Reference Sheet

Pfizer Bivalent Booster (Ages 5-11) - Orange Cap

- Pfizer Vaccine Reference Sheet

Pfizer (Ages 5-11) - Orange Cap

- PEDIATRIC Pfizer Vaccine Reference Sheet

Comirnaty/Pfizer (Ages 12+) - Gray Cap

- Comirnaty/Pfizer Vaccine Reference Sheet

Pfizer Bivalent Booster (Ages 12+, No Diluent) - Gray Cap

- Pfizer Vaccine Reference Sheet



ADHS Vaccine Reference Sheets - Moderna

Moderna Bivalent Booster (Ages 6 months - 5 years) - Dark Pink Cap with Yellow Border on label

- Moderna Vaccine Reference Sheet

Pediatric Moderna Blue Cap with Magenta border on label (Ages 6mo - 5 years)

- Moderna Vaccine Reference Sheet

Pediatric Moderna Blue Cap with Purple Border on label (Ages 6 - 11 years)

- Moderna Vaccine Reference Sheet

Moderna Bivalent Booster *(Ages 6+)* - Blue Cap

- Moderna Vaccine Reference Sheet

Moderna (Ages 12+)

- Moderna Vaccine Reference Sheet



COVID-19 Vaccination Schedule for Primary and Booster Doses

COVID-19 Vaccination Schedule for people who are NOT and who ARE Moderately or Severely Immunocompromised





***For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.**

† A monovalent Novavax booster dose maybe used in limited situations in people 18 years and older who completed a primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable or unwilling to receive an mRNA vaccine. The monovalent Novavax booster dose is administered at least 6 months after completion of a primary series.

‡Janssen COVID-19 dose should only be used in certain limited situations. See: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a

COVID-19 Vaccine Program

ADHS COVID-19 Vaccine Website

azhealth.gov/covid19vaccine





ADHS Find Vaccine webpage azhealth.gov/findvaccine

- The locations of vaccination sites
- Filter to sort by vaccine type
- Use the patient portal at podvaccine.azdhs.gov to make an appointment for a relative
- Appointments recommended but no longer required at state-operated sites



Pandemic Provider Onboarding Start Form

- All facilities must onboard to be able to order/administer COVID-19 vaccines
- Pandemic Vaccine Provider Onboarding Tool - Job Aid (bottom right)
- Wait until you're at the facility to onboard so you can upload photos of inside and outside of units
- Read through forms for important requirements
- Note: Per the CDC Agreement, COVID-19 vaccines must be recorded in the vaccine recipient's record, the required information reported to the relevant state, local, or territorial public health authority, and decremented from the inventory **within 24 hours of administration**.



ARIZONA DEPARTMENT OF HEALTH SERVICES

Pandemic Vaccine Provider Onboard Form 1

The Arizona Immunization Program Office (AIPO) does not know if/when COVID-19 vaccines will become available. However we want to be prepared and engage our partners now, so we are ready when vaccines are available for distribution in Arizona.

Both VFC and non-VFC providers who would like to administer future COVID-19 vaccines must complete the Pandemic Provider Onboarding survey forms.

After submitting this form, you will be sent to a page with a series of subsequent survey forms. The forms serve two purposes: 1) to ensure the signatory provider knows the requirements, and 2) to ensure the facility is able to meet each requirement. The signatory provider is required to complete all of the surveys and be approved by the AIPO before this facility will be able to order future potential pandemic vaccines.

As we learn more about future vaccines we may add additional survey forms to the onboarding tool to pass the information along.

Onboarding is not an instantaneous process. It will take AIPO time to add providers to ASIIS and review requirements. Onboard now. Plan for it to take time.

The onboarding tool has the high level requirements for the signatory provider. Provider staff can go to AIPO Train to learn how to order, receive, store, administer, document, and account for pandemic vaccines in ASIIS.

We appreciate your continued efforts to help Arizonans be healthy and vaccinated.

Click the link to view the onboard Job aid to help you complete the survey forms. You are currently on Form 1.
Please contact our help desk if you have further questions: (602) 364-3899



ARIZONA DEPARTMENT OF HEALTH SERVICES
PREPAREDNESS

Pandemic Vaccine Provider Onboarding Tool

How to get started

1. Click the onboarding link Pandemic Vaccine Provider Onboard Form 1 and fill out the form
2. Click submit - this will take you to survey queue page
3. Continue to complete other surveys that are not marked "Complete." A link to this page will be emailed to you

1 Contact and Shipping Information
- Facility location information
- Signatory provider info (title, license, NPI)
- Primary and backup vaccine coordinator information
- Not sure if you're a VFC/VCA provider? Select no when it asks if you are a VFC provider; this is not necessary to participate

2 Storage and Handling
- Photos of your cold storage units showing the inside of the units
- Brand and model of each cold storage unit
- Data logger usage info
- Read requirements

3 Arizona State Immunization Information System (ASIIS)
- Are you currently entering/transferring immunization data into ASIIS?
- Read requirements

4 Vaccine Planning
- Read through content so you can plan and be prepared

5 CDC Agreement Section A
- CMO & CEO signatures
- For organizations: follow the instructions for Section A in FAQs. Follow the decision tree on the final page to determine whether you need to follow organization instructions

6 CDC Agreement Section B
- Facility type
- Populations served
- Storage unit capacity
- Must be signed by the signatory provider/the primary vaccine coordinator

7 Prescribing Providers (part of CDC Agreement)
- Submit multiple times - one for each prescribing provider
- Enter each prescriber's name, title, and license number

Revised November 2020



FAQs

I clicked "Save and Return" and lost my place. What do I do?
- Find the email with the link to the survey queue page
- Click the survey queue page link
- Click on the survey you were working on
- Enter return code
- Continue survey
- If you did not save a return code, click the "start over" button to start the survey form again. You will not lose previously submitted survey forms

How will I know if I'm done?
- On the survey queue page, surveys marked "Complete" are done and surveys with a "Begin Survey" button are incomplete.

What training do I need?
- The AIPO TRAIN has training courses for staff who are responsible for daily tasks, including:
  - How to order, receive, and account for doses in ASIIS
  - How to use data loggers
  - Storage & handling requirements
- Facilities are responsible for knowing and following the guidelines in the AIPO TRAIN training modules

What are the instructions for group organizations with several facility locations?
- The CDC Provider Agreement has Section A and Section B
- CMO & CEO for organizations must complete and sign Section A only once for all facility locations within the organization
- Select one facility location whose survey form will be used
- Inform the other facilities which facility location was selected
- Share the link for the survey with the CMO & CEO
- Use the "Sign and return later" button to allow both the CMO & CEO to sign the same survey form
- After the Section A survey form is signed and submitted by the CMO & CEO, a code number will be emailed to the CMO & CEO
- Have the CMO & CEO forward the email with the code number to all of the organization's facility locations
- The other facilities will enter the code number that was forwarded to them into the survey form titled "Enter code" from section A
- Complete all other sections of the CDC Agreement and onboard survey forms

NOTE: Facilities that are part of an Organization must ensure that their CMO & CEO complete a section A survey form for their Organization. No COVID-19 vaccines will be shipped to facilities whose organization has not completed/signed section A

COVID vaccinators will need to be enrolled with AHCCCS in order to be able to bill the vaccine administration fee for AHCCCS beneficiaries.
Providers can register with AHCCCS at: https://www.azahcccs.gov/PlansProviders/APEP/Access.html

Revised November 2020

Required Reporting

- ASIIS
  - for inventory accounting and dose administration data within 24 hours
    - Required even if you use an EHR, ADHS VMS app, etc.
    - Verify ASIIS Lot Number > Reconciliation page (ASIIS Inventory) numbers should be matched between the quantity on hand and physical inventory columns
      - Vaccine Inventory Management course in AIPO Train
- Vaccines.gov/CDC VaccineFinder weekly inventory by Fridays
- County surveys as required by your local jurisdiction

Your ASIIS inventory is used by local, state, and federal leaders to make vaccine ordering decisions - It MUST be accurate

COVID-19 Inventory Management Reminders

In order to ensure that provider sites are being good stewards of the COVID-19 vaccines, the CDC has emphasized that each COVID-19 vaccination site should have at most 3-4 weeks of vaccine inventory on hand.

- Place smaller, more frequent orders to avoid stockpiling doses
- Use the data in ASIIS to determine how many doses you use & how many doses are on hand to place an order for an appropriate amount of doses
- Use the ADHS vaccine transfer matchmaker website to request a smaller quantity of doses then can be ordered in ASIIS
- Administered doses must be entered in ASIIS within 24 hours and decremented from the ASIIS inventory
- CDC VaccineFinder (vaccines.gov) inventory must be updated weekly by Friday
- Wasted/Expired Doses must be reported on signed and complete wasted/expired forms weekly

Off-Label Use

Pandemic providers should be aware that they must use COVID-19 vaccines according to FDA and CDC guidance. Use of COVID-19 vaccines outside of FDA and CDC recommendations ("off label") is a violation of the provider agreement.

- Providers may not be covered under PREP Act and therefore not have the immunity from prosecution that the PREP Act provides.
- Recipients of an "off-label" COVID-19 vaccine dose may not be covered by the Countermeasure Injury Compensation Program if they were to have serious adverse events from the vaccine.
- Providers who violate the CDC agreement may not be able to remain as part of CDC programs.
- COVID-19 vaccine administration fees may not be covered if the dose were given "off-label."

CDC Website: VFC vs. COVID-19 Vaccination Programs

- Separate programs with separate agreements
- Distinct requirements for each
- Help VFC providers understand difference between program requirements

Vaccines & Immunizations

CDC > COVID-19 Vaccination > Provider Requirements and Support

COVID-19 Vaccination
- Product Info by U.S. Vaccine +
- Clinical Care +
- Provider Requirements and Support –
  - How to Enroll as a Healthcare Provider
  - Inventory Management Best Practices
  - Vaccines for Children Program vs. CDC COVID-19 Vaccination Program
- Training and Education +
- Vaccine Recipient Education +
- Health Departments +
- Planning & Partnerships +
- Vaccine Effectiveness Research
- Vaccination Toolkits +

Vaccines for Children Program vs. CDC COVID-19 Vaccination Program

As Emergency Use Authorization of COVID-19 vaccine products expand to include adolescents and children, it is critical to enroll providers in the COVID-19 Vaccination Program to ensure equitable access to COVID-19 vaccination services . Providers enrolled in the Vaccines for Children (VFC) program are well situated to serve in this capacity due to their direct access to the younger patient population and their familiarity with vaccine administration and federal vaccine programs. Though the VFC and COVID-19 Vaccination programs are both federal government programs, they each have distinct requirements based on the associated funding legislation. For this reason, the provider agreements remain separate, and VFC providers must sign and adhere to the requirements of the *CDC COVID-19 Vaccination Program Provider Agreement* in order to receive and administer COVID-19 vaccines. The table below has been developed to assist VFC providers in understanding the difference in the programs' requirements. **Program differences are in bold.**

	VFC Program	COVID-19 Vaccination Program
Provider Enrollment	• Providers enroll via state/local immunization program enrollment system and procedures. • **Providers must complete and sign state/local immunization program *Vaccines for Children Program Provider Agreement* and *VFC Program Provider Profile Form.***	• Providers enroll via state/local immunization program enrollment system and procedures. • **Providers must complete and sign *CDC COVID-19 Vaccination Program Provider Agreement,* Sections A and B.**
Vaccine Ordering	• Providers order routine childhood vaccines via state/local immunization program-designated ordering system and procedures.	• Providers order COVID-19 vaccines via state/local immunization program-designated ordering system and procedures. • Providers must be fully trained in vaccine

Vaccines.gov/CDC VaccineFinder Provider Resources

The "organization email" listed in Section A of the CDC Agreement will get an email from vaccinefinder@auth.castlighthealth.com to sign up

- Weekly reporting by Friday of on-hand inventory quantities is a requirement
- Activating a location to display to the public is optional
- Providers can update display to the public function at any time
- Once COVID-19 vaccine locations are launched in Vaccines.gov, changes show publicly within 24 hours
- Check phone number in provider portal before making site public
- Vaccines.gov homepage - patients can find vaccines
- NOTE: If a site that is set to display to the public fails to update inventory within 72 hours, the availability information for each vaccine will display as "Call to confirm" on Vaccines.gov.

COVID-19 Administration Reporting Systems (CARS) Help Desk

- Monday through Friday, 8:00 am to 8:00 pm ET.
- CARS_HelpDesk@cdc.gov
- 1-833-748-1979
- Provide PIN when calling



Changes to the Required Temperature Incident Reporting Process for COVID-19 Vaccine Temperature Incidents

The Bureau of Immunization Services (BIZS) is introducing changes to the required temperature incident reporting process for COVID-19 vaccine temperature incidents. This process is intended to improve incident turnaround times for providers by allowing them to take ownership of the process by following the steps in the Temperature Incident Instructions Checklist to obtain a viability determination from the manufacturer.

This is a required process for reporting all temperature incidents involving COVID-19 vaccines. The BIZS also encourages you to please fill out the survey at the end of the process as we value your feedback.



Incident Report Checklist

AIPO

https://redcapaipo.azdhs.gov/surveys/?s=AY3C74XEPTWDXJ4H

ArizonaVFC@azdhs.gov

602.364.3642

Temperature Incident Instructions

1. Isolate the vaccines in the affected unit, label them DO NOT USE and keep them in the affected unit. Do not administer any doses exposed to out of range temperatures.

2. Download the data logger report(s) from the data logger monitoring the affected unit(s).

3. Determine how long the unit was out of appropriate temperature range and the highest and/or lowest out of range temperature documented on the data logger report.
   - If any vaccines in the affected unit have been involved in a previous temperature incident, you will need to include the time of the previous incident and the highest/lowest out of range temperature the vaccines were exposed to in your report to the manufacturer(s).

Appropriate temperature ranges:
- Refrigerator: 2.0°C to 8.0°C **OR** 36.0°F to 46.0°F
- Standard Freezer: -50.0°C to -15.0°C **OR** -58.0°F to 5.0°
- Ultra Low Temp Freezer: -130.0°F to -76.0F **OR** -90.0°C to -60.0°C

4. Create a list of all affected vaccines - include the type of vaccine, the lot numbers, the expiration dates and the manufacturers.

5. Contact each manufacturer - provide them with the information you obtained from the data logger reports (length of time vaccines were exposed to out of range temperatures and the highest and/or lowest temperature recorded), as well as affected vaccine information, and any previous incident information as requested.

6. If reporting the incident to the manufacturer via phone or through email - request a statement of viability be emailed to you by the manufacturer(s). If you are able to check the viability online with an excursion tool from the manufacturer, download a copy of the viability statement for ALL affected vaccines.

7. Report the outcome of the incident to the AIPO at this link: https://redcapaipo.azdhs.gov/surveys/?s=AY3C74XEPTWDXJ4H

8. If the affected vaccines are deemed viable and the information reported to the manufacturers and the AIPO was accurate, you may resume use of viable vaccines once the incident has been reported to the AIPO using the above link in step 7.

Daily COVID-19 Vaccine Tasks

Temperature Monitoring

- Twice per day monitor temperatures using the approved data logger
  - Document that you monitored temperatures using the paper temp log
    - Comirnaty/Pfizer ULT Celsius Fahrenheit
    - Refrigerator Celsius Fahrenheit
    - Moderna Freezer Celsius Fahrenheit
    - Document current, min, max, time, and initials
- **If there are out of range temperatures, stop using the vaccines and submit an incident report to the BIZS**
- Twice per month download and save the data logger data reports
  - Keep the data logger reports readily available for 6 years
    Submit the data logger reports (in an acceptable file format: .xls, .txt, .ltd or .csv) to the BIZS upon request

Take a physical inventory count of doses in the cold storage units

- Compare the physical count to ASIIS lot number reconciliation inventory
- The inventories should be the exact same if doses given are entered properly in ASIIS. If you need to troubleshoot, use this job aid.
- Enter the weekly inventory by Fridays into CDC Vaccines.gov

Document doses administered in ASIIS within 24 hours

- Shipments must be marked “received” in ASIIS prior to administration in order for the doses to decrement from the inventory

If you would no longer like to participate as a pandemic provider please follow these steps

1. **Account for all doses in ASIIS**
   a. You are responsible for accounting for ALL of the doses shipped to you
   b. Ensure all doses shipped to the facility were received in ASIIS
   c. Ensure all doses administered were decremented from the ASIIS inventory
   d. ASIIS inventory reconciliation screen should be accurate

2. **If you still have doses**
   a. The doses will need to be transferred to another COVID-19 provider
   b. Transfers must have prior approval in ASIIS

3. **Enter zero in CDC Vaccines.gov inventory when your inventory is depleted**

4. **Notify ADHS *after* doses have been accounted for**

AIPO Train

- Training on ordering, receiving, and accounting for doses in ASIIS
- Information on data loggers - setting up, downloading data
- Onboarding resources
- Mass immunizations

How to Register

1. Go to https://AIPO.myabsorb.com/?KeyName=PandemicProviders (This link automatically enters the enrollment key)
2. Enter required fields
3. Select Sign up
4. Click email activation link (important)

How to Log In

1. Go to https://AIPO.myabsorb.com/#/login
2. Enter username and password (username will be email address)
3. Select Log In

For existing AIPO Train users: Enter enrollment key “PandemicProviders” to access pandemic-specific training

Questions? Email AIPOTrain@azdhs.gov

Administration Fee

- CMS has a toolkit to help health care providers prepare to administer vaccines
- Vaccine doses given to the American people at no cost
- Providers contractually agree to administer a COVID-19 vaccine regardless of an individual's ability to pay and regardless of their coverage status
- May not seek any reimbursement, including through balance billing, from a vaccine recipient
- People without health insurance can get COVID-19 vaccine at no cost
- If you give COVID-19 vaccines to patients who are covered by **AHCCCS** you will need to be enrolled with AHCCCS in order to bill AHCCCS the administration fee
    - Register with AHCCCS here

Facilities cannot bill patients for the cost or admin fee for COVID-19 vaccines.

CVX Code and CPT Code Resources

- CMS - Helpful for Billing
- CDC - Helpful for Uploading Data in EHR and ASIIS
- ADHS - Arizona HL7 Specific Rules

TAPI - The Arizona Partnership for Immunizations (State immunization coalition)

- COVID-19 Resources
- COVID-19 Vaccine Billing Policy Information
- Resources for immunizations at off-site locations

CDC Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations

CDC has issued revised Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations to assist with jurisdictional planning and implementation of satellite, temporary, or off-site vaccination clinics by public and private vaccination organizations.

The guidance is broken down into four categories:

- Planning activities
- Pre-clinic activities
- During the clinic activities
- Post-clinic activities

The guidance also provides information on additional considerations required during the COVID-19 pandemic, including physical distancing, personal protective equipment (PPE), and enhanced sanitation efforts

Training for Healthcare Professionals

- CDC COVID-19 Vaccine Training Modules
- Public Health Foundation Training Plan





Immunization Action Coalition - immunize.org

- Info on administering vaccines
- Handouts for staff and patients
- “Ask the Experts” page
  - Includes COVID-19 vaccines
- Option to sign up for IAC Express email
  - Weekly email with updates to information and resources

CDC COVID-19 Vaccination Clinical Resources

COVID-19 Vaccination

Clinical Resources for Each COVID-19 Vaccine

Find information for COVID-19 vaccination administration, storage and handing, reporting, and patient education for each specific vaccine

Product Information by US Vaccine

ACIP Recommendations

Storage and Handling

General Vaccine Administration

Training and Education

- V-safe
- Clinical Considerations
- Emergency Use Authorizations (EUAs)
- Vaccination Provider Requirements & Support
- Vaccination Data & Reporting Systems
- Planning & Partnerships

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States

Other resources:

- Summary Document for Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States
- COVID-19 Vaccine Administration Errors and Deviations

Summary Document for Interim Clinical Considerations

for Use of COVID-19 Vaccines Currently Authorized or Approved in the United States

CDC

COVID-19 vaccine products currently approved or authorized in the United States

Pfizer-BioNTech

Age indication	Vaccine composition	Vaccine vial cap color	Label border color	Dilution required	Primary series		Booster doses	
					Dose	Injection volume	Dose	Injection volume
6 months–4 years	Monovalent (Use for 1st and 2nd Dose)*	Maroon	Maroon	Yes	Doses 1 and 2: 3 μg/0.2 m		A booster dose is not authorized for children who received a 3-dose primary series regardless which vaccine (monovalent or bivalent) was administered for Dose 3.	
6 months–4 years	Bivalent (Use for 3rd Dose)	Maroon	Maroon	Yes	Dose 3: 3 μg/0.2 mL			
5–11 years	Monovalent	Orange	Orange	Yes	10 μg	0.2 mL	NA	NA
5–11 years	Bivalent	Orange	Orange	Yes	NA	NA	10 μg	0.2 mL
12 years and older	Monovalent	Gray	Gray	No	30 μg	0.3 mL	NA	NA
12 years and older	Bivalent	Gray	Gray	No	NA	NA	30 μg	0.3 mL

Moderna

Age indication	Vaccine composition	Vaccine vial cap color	Label border color	Dilution required	Primary series		Booster doses	
					Dose	Injection volume	Dose	Injection volume
6 months–5 years	Monovalent	Dark blue	Magenta	No	25 μg	0.25 mL	NA	NA
6 months–5 years	Bivalent*	Dark pink	Yellow	No	NA	NA	10 μg	0.2 mL
6-11 years	Monovalent	Dark blue	Purple	No	50 μg	0.5 mL	NA	NA
6-11 years	Bivalent	Dark blue	Gray	No	NA	NA	25 μg	0.25 mL
12 years and older	Monovalent	Red	Light blue	No	100 μg	0.5 mL	NA	NA
12 years and older	Bivalent	Dark blue	Gray	No	NA	NA	50 μg	0.5 mL

CDC Vaccine Storage and Handling Toolkit

Get Email Updates

To receive email updates about this page, enter your email address:

Email Address

What's this? Submit

Related Links

Vaccines & Immunizations

View or Print Toolkit

The Vaccine Storage and Handling Toolkit is a comprehensive guide that reflects best practices for vaccine storage and handling from Advisory Committee on Immunization Practices (ACIP) recommendations, product information from vaccine manufacturers, and scientific studies.

Vaccine Storage and Handling Resources

Access additional resources including web-based trainings, videos, checklists, and references related to vaccine storage and handling.

These example vaccine labels can be used to organize vaccines within the storage unit. Referenced in the storage and handling toolkit.

- 2020-2021 Influenza Season Vaccine Label Examples [4 pages] (Sept 2020)
- Vaccine Labels Examples [20 pages] (Jan 2021)



View, download, and print the 2021 Vaccine Storage and Handling Toolkit.

More

Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites

- Emergency equipment that should be immediately available
- Routine observation periods following COVID-19 vaccination
- Early recognition of anaphylaxis
- Management of anaphylaxis at a COVID-19 vaccination location
- Considerations for anaphylaxis management in special populations
- Patient counseling
- Reporting anaphylaxis

Locations administering COVID-19 vaccines should adhere to CDC guidance, including screening recipients for contraindications and precautions, having necessary supplies and staff members available to manage anaphylaxis, implementing recommended post vaccination observation periods, and immediately treating suspected anaphylaxis with intramuscular epinephrine injection.

CDC v-safe system

- Give patients a **v-safe** information sheet at the time of vaccination
- Suggested healthcare provider script**:** *CDC has created a way for you to report how you feel after COVID-19 vaccination through a smartphone-based tool that uses text messaging and web surveys to check in with you. Here (or in your packet) is a **v-safe** information sheet with more details and simple instructions to sign up.*
- Parents and guardians can now enroll adolescents (ages 5 and older) in the v-safe after vaccination health checker℠ and complete health check-ins on their behalf after COVID-19 vaccination.
- Poster and website translated into multiple languages

Get vaccinated. Get your smartphone. Get started with v-safe.

What is v-safe?

V-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after you receive a COVID-19 vaccination. Through ***v-safe***, you can quickly tell CDC if you have any side effects after getting the COVID-19 vaccine. Depending on your answers, someone from CDC may call to check on you. And ***v-safe*** will remind you to get your second COVID-19 vaccine dose if you need one.

Your participation in CDC's ***v-safe*** makes a difference—it helps keep COVID-19 vaccines safe.

How can I participate?

Once you get a COVID-19 vaccine, you can enroll in ***v-safe*** using your smartphone. Participation is voluntary and you can opt out at any time. You will receive text messages from ***v-safe*** around 2pm local time. To opt out, simply text "STOP" when ***v-safe*** sends you a text message. You can also start ***v-safe*** again by texting "START."

How long do v-safe check-ins last?

During the first week after you get your vaccine, ***v-safe*** will send you a text message each day to ask how you are doing. Then you will get check-in messages once a week for up to 5 weeks. The questions ***v-safe*** asks should take less than 5 minutes to answer. If you need a second dose of vaccine, ***v-safe*** will provide a new 6-week check-in process so you can share your second-dose vaccine experience as well. You'll also receive check-ins 3, 6, and 12 months after your final dose of vaccine.

Is my health information safe?

Yes. Your personal information in ***v-safe*** is protected so that it stays confidential and private.*

*To the extent ***v-safe*** uses existing information systems managed by CDC, FDA, and other federal agencies, the systems employ strict security measures appropriate for the data's level of sensitivity. These measures comply, where applicable, with the following federal laws, including the Privacy Act of 1974; standards enacted that are consistent with the Health Insurance Portability and Accountability Act of 1996 (HIPAA); the Federal Information Security Management Act, and the Freedom of Information Act.

12/01/20

v-safe℠
after vaccination health checker

Use your smartphone to tell CDC about any side effects after getting the COVID-19 vaccine. You'll also get reminders if you need a second vaccine dose.

Sign up with your smartphone's browser at

OR

Aim your smartphone's camera at this code

VAERS Reporting and Safety Info - vaers.hhs.gov

VAERS accepts all reports from everyone regardless of the plausibility of the vaccine causing the event or the clinical seriousness of the event.



EUA Fact Sheets

Routine vaccines are given with a Vaccine Information Statement (VIS)
COVID-19 vaccines under the Emergency Use Authorization (EUA) will be given with an EUA Factsheet.

- Pfizer Bivalent Booster Gray Cap (Ages 12+, No Diluent) EUA Fact Sheet
- Comirnaty/Pfizer Gray Cap (ages 12+) EUA Fact Sheet
- Pfizer Orange Cap (ages 5-11yrs) EUA Fact Sheet
- Pediatric Pfizer Bivalent Booster Orange Cap (Ages 5 - 11yrs) EUA Fact Sheet
- Pfizer Maroon Cap Monovalent & Bivalent (ages 6mos-4yrs) EUA Fact Sheet
    - Pfizer EUA fact sheets translated in other languages
- Moderna Bivalent Booster Blue Cap (Ages 6+) EUA Fact Sheet
- Moderna Bivalent Booster Dark Pink Cap (Ages 6mos-5yrs) EUA Fact Sheet
- Moderna (ages 12+) EUA Fact Sheet
- Moderna (ages 6-11) EUA Fact Sheet
- Moderna (ages 6mos-5yrs) EUA Fact Sheet
    - Moderna EUA fact sheets translated in other languages
- Janssen EUA Fact Sheet
    - Janssen EUA fact sheet translated in other languages
- Novavax EUA Fact Sheet
    - Novavax EUA fact sheet translated in other languages

FDA gives Moderna COVID-19 vaccine full approval for use in ages 18 and older

- The Food and Drug Administration (FDA) has given full approval to the Moderna COVID-19 vaccine for use in those ages 18 and older. Ages 6mos to 17 are eligible for Moderna COVID-19 vaccines under FDA emergency use authorization.

- Moderna joins the Pfizer-BioNTech vaccine, which the FDA gave full approval to last August for use in ages 16 and older. Ages 6mos to 15 are eligible for Pfizer COVID-19 vaccines under FDA emergency use authorization.

Moderna Label Update

FDA recently approved updates to both label and the EUA fact sheet for the Moderna COVID-19 vaccine. Distribution of the Moderna vials with the updated labels (see new label above) began during the week of January 13, 2021.

What has changed on the label of the Moderna COVID-19 vaccine:

- The label has been updated to indicate a volume of 5.5mL.
- Doses for primary series and booster shots are now listed on the label.
- Important reminder not to exceed a maximum of 20 punctures per vial

For more information, please refer to the [EUA fact sheet](#) or [Administration Overview for Moderna COVID-19 Vaccine | CDC](#).

What remains the same for the Moderna COVID-19 vaccine:

- Formulation
- NDC
- Physical vial size
- Number of reportable doses
- Dose volumes (See Below)
- Reporting requirements
  - Wastage should continue to be reported based on 10 doses per vial.
- Proper dosage of Moderna COVID-19 Vaccine
  - Primary series doses 1 and 2 dosage = 0.5 mL
  - Additional primary dose (3rd) dosage for immunocompromised persons = 0.5 mL
  - Booster dosage = 0.25 mL
- Each vial can ONLY be punctured up to 20 times.
  - Once the vial has reached the 20-puncture limit, the vial should be discarded **even if there is vaccine remaining in the vial**.

Moderna Booster Reporting of Administered and Wasted Doses

- Quick rule of thumb: As long as the vial has been punctured 10 or 14 times and 10 or 14 doses were administered (regardless if they were full primary series doses or half booster doses) there will be no reported wastage.
- Example from the 14 dose vial table: 5 full doses (primary series) were administered and 5 half doses (booster doses) were administered before the 12 hour limit was reached. 4 doses should now be reported as wastage.

Moderna 10 Dose Vial Wastage Table

Half Doses \ Full doses	0	1	2	3	4	5	6	7	8	9	10
0	10	9	8	7	6	5	4	3	2	1	0
1	9	8	7	6	5	4	3	2	1	0	
2	8	7	6	5	4	3	2	1	0		
3	7	6	5	4	3	2	1	0			
4	6	5	4	3	2	1	0				
5	5	4	3	2	1	0					
6	4	3	2	1	0						
7	3	2	1	0							
8	2	1	0								
9	1	0									
10	0										
11											
12											
13											
14											
15											
16											
17											
18											
19											
20											

Green Area = No Was

Moderna 14 Dose Vial Wastage Table

Half Doses \ Full doses	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
0	14	13	12	11	10	9	8	7	6	5	4	3	2	1	0
1	13	12	11	10	9	8	7	6	5	4	3	2	1	0	
2	12	11	10	9	8	7	6	5	4	3	2	1	0		
3	11	10	9	8	7	6	5	4	3	2	1	0			
4	10	9	8	7	6	5	4	3	2	1	0				
5	9	8	7	6	5	4	3	2	1	0					
6	8	7	6	5	4	3	2	1	0						
7	7	6	5	4	3	2	1	0							
8	6	5	4	3	2	1	0								
9	5	4	3	2	1	0									
10	4	3	2	1	0										
11	3	2	1	0											
12	2	1	0												
13	1	0													
14	0														
15															
16															
17															
18															
19															
20															

No Waste Reported

Green Area = No Waste Reported

Moderna Puncture Tracking Log

- Keep track of how many times vials have been punctured
- Vials can only be punctured maximum of 20 times
- Mark half-doses vs full doses
- Can track 2 vials per log

Moderna Puncture Tracking Log

Vial Lot #:_____
Start Time: End Time:

Dose	Full (0.5 mL)	Half (0.25 mL)
1	☐	☐
2	☐	☐
3	☐	☐
4	☐	☐
5	☐	☐
6	☐	☐
7	☐	☐
8	☐	☐
9	☐	☐
10	☐	☐
11	☐	☐
12	☐	☐
13	☐	☐
14	☐	☐
15	☐	☐
16	☐	☐
17	☐	☐
18	☐	☐
19	☐	☐
20	☐	☐

Vial Lot #:_____
Start Time: End Time:

Dose	Full (0.5 mL)	Half (0.25 mL)
1	☐	☐
2	☐	☐
3	☐	☐
4	☐	☐
5	☐	☐
6	☐	☐
7	☐	☐
8	☐	☐
9	☐	☐
10	☐	☐
11	☐	☐
12	☐	☐
13	☐	☐
14	☐	☐
15	☐	☐
16	☐	☐
17	☐	☐
18	☐	☐
19	☐	☐
20	☐	☐

Reminders

- Moderna booster doses are 0.25mL (half the dose size of a primary series dose)
- Moderna vials can only be punctured a maximum of 20 times
- Providers are responsible to keep track of the number of punctures for each vial
- Punctured Moderna vials can be used to administer both primary and booster doses
- Punctured Moderna vials must be used within 12 hours

602-364-3899
ArizonaVFC@azdhs.gov
azdhs.gov/covid19/vaccines

Updated 12/2021

Pediatric Pfizer Orange Cap (Ages 5-11) Manufacturing Date vs Expiration Date

- Date printed on vial and tray is **manufacturing date only**
- Base expiration date on storage method and manufacturing date. For example:
  - If the manufacturer date is 8/2021 and the doses are stored in an ultra-low-temp freezer, the doses would expire April 30, 2022.
  - If the doses are put in the refrigerator November 2, 2021, they would expire 10 weeks from November 2 on January 11, 2022.
- Use Pfizer Age 5-11 EUA Fact Sheet (Page 3)
- Use Pfizer website

Pediatric Pfizer Orange Cap (Ages 5-11) Shippers

- Shipper CANNOT be used for temp storage
- Can only be stored in ULT freezers and refrigerators
- Shipper does not need to be returned
- Controlant data logger **does** need to be returned

Do NOT store contents in standard freezer

You can only puncture the diluent once

Orders of Pfizer age 5-11 vaccine include ancillary kits that contain 10mL diluent vials. While these vials appear to contain sufficient diluent for multiple vials, they must only be used once.

- Diluent vials are a one-time-use item and should be discarded with the remaining content after each use.
- For each vial of vaccine, extract 1.3mL of diluent from a single-use vial to reconstitute 1.3mL of vaccine
- Do not be tempted to puncture diluent vials more than once.

COVID-19 Vaccine Transfer Matchmaker Tool

- **Share vaccine with other active COVID-19 providers**
- Request vaccine from nearby locations if active providers need vaccine
- You can transfer needles as well
- Only serves as connection between providers
- **All transfers must still have prior approval in ASIIS, must follow all transfer steps**
- Matchmaker Tool Job Aid
  - Transfer steps
  - Helpful resources linked

COVID-19 Vaccine Transfer Matchmaker

Do you have more vaccines than you can use?
List them on the Arizona COVID-19 Vaccine Transfer Matchmaker Website using the "Add Vaccine/Needle" form on the website.

Do you need to place a vaccine order?
First, check the Arizona COVID-19 Vaccine Transfer Matchmaker Website for vaccine available at a location near you, and submit a "Request Vaccine/Needle" form on the website. The table on the left shows vaccines that are available for providers to request.

72,182
Vaccines requested to date

Arizona COVID-19 Vaccine Available for Transfer

Row ID	County	City	Vaccine/ Needle	Expiration Date	Quantity
1426	Maricopa	Phoenix	Pfizer age 12+	11/30/21	127998
1425	Maricopa	Phoenix	Pfizer age 12+	11/30/21	13440
1424	Maricopa	Phoenix	Pfizer age 12+	11/30/21	16380
1419	Maricopa	Scottsdale	J&J	03/20/22	50
1418	Maricopa	Phoenix	Pfizer age 12+	11/30/21	91104
1416	Maricopa	Phoenix	Pfizer age 12+	11/30/21	64350
1395	Maricopa	Phoenix	J&J	04/09/22	50
1389	Coconino	Flagstaff	Pfizer age 12+	11/07/21	3510
1388	Pima	Green Valley	Pfizer age 12+	11/30/21	670
1372	Maricopa	Phoenix	Pfizer age 12+	11/30/21	35124
1094	Yuma	Yuma	Pfizer age 12+	12/31/21	1080

Add Vaccine/ Needle

What is your name? *
What is your email address? *
What is your phone number? *
What is your ASIIS PIN? *
What city are you located in? *
What county are you located in? *
Select
Which vaccine/needle is available? *
Ancillary kits must be transferred with the vaccines. Please do NOT list needles separately if you are already listing vaccines.
- J&J
- Moderna
- Pfizer age 12+
- Pfizer age 5-11
- 1" needles only (no vaccines)
- 1.5" needles only (no vaccines)

How many doses/needles? *

Request Vaccine/ Needle

What is your name? *
What is your email address? *
What is your phone number? *
What is your ASIIS PIN? *
What is the row ID that you are interested in? *
Ancillary kits must be transferred with the vaccines. You do NOT need to request needles separately if you are requesting vaccines.
How many doses/needles? *
Send me a copy of my responses
Submit

Privacy Notice | Report Abuse

ADHS Consent Form Template

- No Federal requirement for informed consent relating to immunization
- Available for providers who do not have own consent form
- Use with CDC Pre-Vaccination checklist
- Spanish ADHS consent form
- Spanish CDC Pre-Vaccination Checklist

Prevaccination Checklist for COVID-19 Vaccines

CDC

For vaccine recipients:

Patient Name _____

Age _____

The following questions will help us determine if there is any reason you should not get the COVID-19 vaccine today. **If you answer "yes" to any question, it does not necessarily mean you should not be vaccinated.** It just means additional questions may be asked. If a question is not clear, please ask your healthcare provider to explain it.

	Yes	No	Don't know
1. Are you feeling sick today?			
2. Have you ever received a dose of COVID-19 vaccine?			
• If yes, which vaccine product did you receive? ☐ Pfizer ☐ Moderna ☐ Janssen (Johnson & Johnson) ☐ Another product _____			
3. Have you ever had an allergic reaction to: (This would include a severe allergic reaction [e.g., anaphylaxis] that required treatment with epinephrine or EpiPen® or that caused you to go to the hospital. It would also include an allergic reaction that occurred within 4 hours that caused hives, swelling, or respiratory distress, including wheezing.)			

ADHS COVID-19 Vaccine Consent Form

ARIZONA DEPARTMENT OF HEALTH SERVICES
PREPAREDNESS

Use this form in conjunction with the CDC Pre-Vaccination Checklist for COVID-19 Vaccines.

(Staff only) Appointment ID: _____

Patient Information

Last Name | First Name | Middle Name (optional)

Mother's Maiden Name (Optional) | Date of Birth (MM/DD/YYYY) | Gender

Address | Apartment Number | City | State | Zip

◯ No address available

Phone Number

Email Address

Insurance Information

Do you have insurance? ◯ Yes ◯ No

Plan Name | Plan Group ID # | Plan Individual ID #

Name of Person Covered By Plan | Plan Responsible Person Name

Private Insurance Address and Phone Number (If Available)

CONSENT AND ASSIGNMENT OF BENEFITS: *I have had a copy of the Emergency Use Authorization for the COVID-19 vaccine made available to me. I have had a chance to ask questions and I believe I understand the benefits and risks of the COVID-19 vaccines requested. I ask that the vaccines be administered to me or the person for whom I am authorized to make this request.*

I certify that I am: (1) the patient and at least 18 years of age; (2) the legal guardian of the patient and the patient's age makes him/her eligible to receive the vaccine based on the current emergency use authorization; or (3) a person authorized to consent on behalf of the patient where the patient is unable to consent for themselves.

I hereby assign to _____ any insurance or other third-party benefits available for the administration fee of the COVID-19 vaccine provided to me. I agree to forward to _____ all health insurance and other third-party payments I receive for services rendered to me immediately upon receipt.

I agree to allow the health care provider to release information to the Arizona State Immunization Information System (ASIIS) to record that I (or for the person for whom I am authorized to consent) have received this COVID-19 vaccine. This information will help keep track of the manufacturer and doses of the vaccine.

Patient Printed Name | Patient Signature | Date Signed

Parent/Guardian/Authorized Person Printed Name | Authorized Person's Signature | Date Signed

Vaccine Administration Information for Immunizer Use Only

Administration Date | Manufacturer | NDC # | ◯ LEFT ARM ◯ RIGHT ARM

Lot Number | Expiration Date | Route | Site

Administering Immunizer Name and Title | Administering Immunizer Signature

Is this the patient's first, second, or third dose? ◯ First ◯ Second ◯ Third ◯ Booster Dose

ADHS Does Not Provide Exemption Forms for Adults for the COVID-19 Vaccine

- Individual facilities and employers may choose to set their own immunization requirements for adults
- If an employer is requiring a COVID-19 Vaccine for their employees, and the employee is refusing vaccination, direct that patient to their Human Resources department
- Adults who have questions on immunization exemptions, for any vaccine, should contact the facility or employer who has set the requirement

Standing Order Links - Pfizer-BioNTech

[Link to Pfizer (Gray Cap)]

[Link to Pfizer (Orange Cap)]

[Link to Pfizer (Maroon Cap)]



12 Years of Age and Older (Gray Cap)

Pfizer-BioNTech COVID-19 Vaccine

Standing Orders for Administering Vaccine

Vaccine	Diluent	Dosage (amount)/ Route
12 years of age and older (gray cap)	Do **NOT** dilute.	**0.3 mL**/IM injection

Purpose

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure

Assess persons 12 years of age and older for vaccination with Pfizer-BioNTech COVID-19 Vaccine based on the following criteria:

Persons who **ARE NOT** moderately or severely immunocompromised[†]

- If the recipient has never received a COVID-19 vaccine, administer 1 dose of Pfizer-BioNTech COVID-19 Vaccine.
- If the recipient has received 1 previous dose of:
  - Pfizer- BioNTech COVID-19 Vaccine, administer the second dose at least 3 to 8 weeks after the first dose
  - If the first-dose vaccine product cannot be determined or is no longer available, administer Pfizer-BioNTech COVID-19 Vaccine at least 3 to 8 weeks after the first dose.
  - While a 3-week interval remains optimal for moderately to severely immunocompromised persons, adults ages 65 years and older, and others who need rapid protection because of community transmission or risk of disease, an 8-week interval may be optimal for some people, including males 12-39 years of age because of the small risk of myocarditis associated with mRNA COVID-19 vaccines. Vaccine effectiveness may also be increased with an interval longer than 3 weeks.
- If the recipient has received 2 previous doses of Pfizer- BioNTech COVID-19 Vaccine, administer a booster dose at least 5 months
- If the recipient has received 2 doses of Janssen COVID-19 Vaccine and is:
  - 18 – 49 years of age, a booster dose of mRNA vaccine may be given at least 4 months after the previous dose (3 total doses)
  - 50 years of age and older, a booster dose of mRNA vaccine should be given at least 4 months after the previous dose (3 total doses)
- If the recipient has received 2 doses of COVID-19 vaccine (1 dose of Janssen and 1 dose mRNA vaccine) and are 50 years of age and older administer a second mRNA booster dose at least 4 months after the most recent dose. (3 total doses)

Persons who **ARE** moderately or severely immunocompromised[†]

- If the recipient has never received a COVID-19 vaccine, administer 1 dose of Pfizer-BioNTech COVID-19 Vaccine.
- If the recipient has received 1 previous dose of:
  - Pfizer- BioNTech COVID-19 Vaccine, administer the second dose at least 21 days (3 weeks) after the first dose.
  - If the first-dose vaccine product cannot be determined or is no longer available, administer Pfizer-BioNTech COVID-19 Vaccine at least 21 days (3 weeks) after the first dose.
- If the recipient has received:
  - 2 doses of Pfizer-BioNTech Vaccine, administer a third dose at least 28 days (4 weeks) after dose 2
  - 1 dose of Janssen COVID-19 Vaccine, administer Pfizer-BioNTech COVID-19 Vaccine at least 28 days (4 weeks) after Janssen COVID-19 Vaccine.
- If the recipient has received:
  - 3 previous doses of Pfizer- BioNTech COVID-19 Vaccine, administer a booster dose at least 3 months after the dose 3 in the mRNA primary series.
  - 1 dose of Janssen and an additional dose of mRNA vaccine (any product), administer a booster dose at least 2 months (8 weeks) after the additional dose of mRNA vaccine.



5 Through 11 Years of Age

Pfizer-BioNTech COVID-19 Vaccine

Standing Orders for Administering Vaccine

Vaccine	Diluent	Dosage (amount)/ Route
Formulation: 5 through 11 years of age	1.3 mL of 0.9% sodium chloride (normal saline, preservative-free) diluent	0.2 mL/IM injection

Purpose

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure

Assess children 5 through 11 years of age for vaccination with Pfizer BioNTech COVID-19 Vaccine based on the following criteria:

- Primary-series[*]
  - If the recipient has never received a COVID-19 vaccine, administer 1 dose of Pfizer-BioNTech COVID-19 Vaccine.
  - If the recipient has received 1 previous dose of Pfizer-BioNTech COVID-19 Vaccine, administer the second dose at an interval of least 21 days.[†]
- Booster dose[*]
  - Children who are NOT immunocompromised: If the recipient has received 2 previous doses of Pfizer COVID-19 Vaccine, administer a booster dose at least 5 months after dose 2.
  - Children who are moderately or severely immunocompromised: If the recipient has received 2 previous doses of Pfizer COVID-19 Vaccine, administer a booster dose at least 3 months after dose 2.
- Children with a history of myocarditis or pericarditis:
  - If history is prior to COVID-19 vaccination, may receive Pfizer-BioNTech formulation 5 through 11 years of

be considered in certain circumstances after the episode of myocarditis or pericarditis has completely resolved. Considerations can be found at https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-pfizer-biontech-moderna

  - Educational materials on myocarditis/pericarditis are available at http://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html
- Additional primary dose for persons who are moderately or severely immunocompromised
  - Administer an additional primary dose of Pfizer-BioNTech vaccine (orange cap) at least 28 days after the initial 2-dose Pfizer-BioNTech primary series.
- Additional clinical considerations
  - For children who received a COVID-19 vaccine that is not currently authorized or approved in the United States, guidance can be found at: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html#not-authorized-vaccines
  - Pfizer-BioNTech COVID-19 Vaccine may be coadministered with other vaccines without regard to timing, including simultaneous administration.
  - For recommendations for COVID-19 vaccination and SARS-CoV-2 infection, see https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#CoV-19-vaccination

Screen for contraindications and precautions

Contraindications:

History of:

- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to component of the COVID-19 vaccine
- Known diagnosed allergy to a component of the vaccine



6 Months Through 4 Years of Age

Pfizer-BioNTech COVID-19 Vaccine

Standing Orders for Administering Vaccine

Vaccine	Diluent	Dosage (amount)/ Route
Formulation: 6 months through 4 years of age	2.2 mL of 0.9% sodium chloride (normal saline, preservative-free) diluent	0.2 mL/IM injection

Purpose

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure

Assess children 6 months through 4 years of age for vaccination with Pfizer BioNTech COVID-19 Vaccine based on the following criteria:

- Children who ARE NOT moderately or severely immunocompromised[†]
  - Primary Series
    - If the recipient has never received a COVID-19 vaccine, administer 1 dose of Pfizer-BioNTech COVID-19 Vaccine.
    - If the recipient has received 1 previous dose of Pfizer-BioNTech COVID-19 Vaccine, administer the second dose at least 3–8 weeks after Dose 1.
    - If the recipient has received 2 previous doses of Pfizer-BioNTech Vaccine, administer the third dose at least 8 weeks after Dose 2.
- Children who ARE moderately or severely immunocompromised[†]
  - Primary Series
- Children with a history of myocarditis or pericarditis:
  - If history is prior to COVID-19 vaccination, may receive Pfizer-BioNTech formulation 6 months through 4 years of age after the episode of myocarditis or pericarditis has completely resolved.
  - If myocarditis or pericarditis occurred after the first dose of an mRNA vaccine, experts advise no additional doses of any COVID-19 vaccine. If, after a risk assessment, a decision is made to administer a subsequent dose of COVID-19 vaccine, vaccine should not be administered until the myocarditis or pericarditis has resolved. Clinical considerations can be found at www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-pfizer-biontech-moderna
- Additional clinical considerations
  - For children who received a COVID-19 vaccine that is not currently authorized or approved in the United States, guidance can be found at: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html#not-authorized-vaccines
  - Pfizer-BioNTech COVID-19 Vaccine may be coadministered with other vaccines without regard to timing, including simultaneous administration.
  - For recommendations for COVID-19 vaccination and SARS-CoV-2 infection, see https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#CoV-19-vaccination

Screen for contraindications and precautions

Contraindications:

History of:

- Severe allergic reaction (e.g., anaphylaxis) after a previous dose

Standing Order Links - Moderna

Link to Moderna (Ages 18+)

Link to Moderna Ages 12-17

Link to Moderna Ages 6-11

Link to Moderna Ages 6mos - 5yrs

Moderna COVID-19 Vaccine
Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older

Vaccine	Dosage (amount)/ Route
Moderna-Primary Series	**0.5 mL**/IM injection
Moderna-Booster Dose	**0.25mL**/IM injection

Purpose

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure

Assess persons 18 years of age and older for vaccination with Moderna COVID-19 Vaccine based on the following criteria:

Persons who **ARE NOT** moderately or severely immunocompromised[1]

- If the recipient has never received a COVID-19 vaccine, administer 1 dose of Moderna COVID-19 Vaccine.
- If the recipient has received 1 previous dose of:
  - Moderna COVID-19 Vaccine, administer the second dose at least 4 to 8 weeks after the first dose
  - If the first-dose vaccine product cannot be determined or is no longer available, administer Moderna COVID-19 Vaccine at least 4 to 8 weeks after the first dose.
  - While a 4-week interval remains optimal for moderately to severely immunocompromised persons, adults ages 65 years and older, and others who need rapid protection because of community transmission or risk of disease, an 8-week interval may be optimal for some people, including males 12-39 years of age because of the small risk of myocarditis associated with mRNA COVID-19 vaccines. Vaccine effectiveness may also be increased with an interval longer than 4 weeks.
- If the recipient has received 2 previous doses of Moderna COVID-19 Vaccine, administer a booster dose at least 5 months after dose 2.
- If the recipient has received 3 previous doses of Moderna COVID-19 Vaccine (2 primary series doses and a booster), administer a second booster dose to persons 50 years of age or older
  - 18 – 49 years of age, a booster dose of mRNA vaccine may be given at least 4 months after the previous dose (3 total doses)
  - 50 years of age and older, a booster dose of mRNA vaccine should be given at least 4 months after the previous dose (3 total doses)
- If the recipient has received 2 doses of COVID-19 vaccine (1 dose of Janssen and 1 dose mRNA vaccine) and are 50 years of age and older administer a second mRNA booster dose at least 4 months after the most recent dose. (3 total doses)

Persons who **ARE** moderately or severely immunocompromised[1]

- If the recipient has never received a COVID-19 vaccine, administer 1 dose of Moderna COVID-19 Vaccine.
- If the recipient has received 1 previous dose of:
  - Moderna COVID-19 Vaccine, administer the second dose at least 4 weeks (28 days) after the first dose.
  - If the first-dose vaccine product cannot be determined or is no longer available, administer Moderna COVID-19 Vaccine at least 4 weeks (28 days) after the first dose.
- If the recipient has received:
  - 2 doses of Moderna Vaccine, administer a third dose at least 28 days (4 weeks) after dose 2
  - 1 dose of Janssen COVID-19 Vaccine, administer Moderna COVID-19 Vaccine at least 28 days (4 weeks) after Janssen COVID-19 Vaccine.
- If the recipient has received:
  - 3 previous doses of Moderna COVID-19 Vaccine, administer a booster dose at least 3 months after dose 3 in the mRNA primary series
  - 1 dose of Janssen and an additional dose of mRNA vaccine (any product), administer a booster dose at least 2 months (8 weeks) after the additional dose of mRNA vaccine.
- If the recipient has received:
  - 4 previous doses of Moderna COVID-19 Vaccine (3 primary series doses and a booster), administer a second booster dose at least 4 months after the most recent dose. (5 total doses)
  - 1 dose of Janssen, an additional dose of mRNA vaccine, and 1

12 Years Through 17 Years of Age
Moderna COVID-19 Vaccine
Standing Orders for Administering Vaccine

Vaccine	Dosage (amount)/ Route
12 years through 17 years of age (red vial cap with blue bordered label)-	0.5 mL/IM injection

Purpose

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure

Assess children 12 through 17 years of age for vaccination with Moderna COVID-19 Vaccine based on the following criteria:

- Persons who ARE NOT moderately or severely immunocompromised[1]
  - If the recipient has never received a COVID-19 vaccine, administer 1 dose of Moderna COVID-19 Vaccine.
  - If the recipient has received 1 previous dose of Moderna COVID-19 Vaccine, administer the second dose at least 4–8 weeks after Dose 1.
- Persons who ARE moderately or severely immunocompromised[1]
  - If the recipient has never received a COVID-19 vaccine, administer 1 dose of Moderna COVID-19 Vaccine.
  - If the recipient has received 1 previous dose of Moderna COVID-19 Vaccine, administer the second dose at least 4 weeks after Dose 1.
  - If the recipient has received 2 previous doses of Moderna Vaccine, administer the third dose at least 4 weeks after Dose 2.
- Persons with a history of myocarditis or pericarditis:
  - If history is prior to COVID-19 vaccination, may receive
  - If myocarditis or pericarditis occurred after the first dose of an mRNA vaccine, experts advise no additional doses of any COVID-19 vaccine, including Moderna product for children 12 through 17 years of age. Administration of the second dose of an mRNA COVID-19 vaccine series can be considered in certain circumstances after the episode of myocarditis or pericarditis has completely resolved. Considerations can be found at www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-Moderna-moderna
- Additional clinical considerations
  - For persons who received a COVID-19 vaccine that is not currently authorized or approved in the United States, guidance can be found at: www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html#not-authorized-vaccines.
  - Moderna COVID-19 Vaccine may be coadministered with other vaccines without regard to timing, including simultaneous administration.
  - For recommendations for COVID-19 vaccination and SARS-CoV-2 infection, see www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#CoV-19-vaccination.

Screen for contraindications and precautions

Contraindications:

History of:

- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to component of the COVID-19 vaccine
- Known diagnosed allergy to a component of the vaccine (see www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#Appendix-C for a list of vaccine components)

Precautions:

Most people determined to have a precaution to a COVID-19 vaccine at their appointment can and should be administered

6 Years through 11 Years of Age
Moderna COVID-19 Vaccine
Standing Orders for Administering Vaccine

Vaccine	Dosage (amount)/ Route
6 years through 11 years of age (blue vial cap with purple-bordered label)	0.5 mL/IM injection

NOTE:

- Vial label states booster doses only, which are authorized for persons ages 18 years and older.
- FDA has also authorized this product for primary series doses for children ages 6 years through 11 years.
- This is NOT authorized for booster doses for persons 6 months through 17 years.

Purpose

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure

Assess children 6 through 11 years of age for vaccination with Moderna COVID-19 Vaccine based on the following criteria:

- Children who ARE NOT moderately or severely immunocompromised[1]
  - If the recipient has never received a COVID-19 vaccine, administer 1 dose of Moderna COVID-19 Vaccine.
  - If the recipient has received 1 previous dose of Moderna COVID-19 Vaccine, administer the second dose at least 4–8 weeks after Dose 1.
- Children who ARE moderately or severely immunocompromised[1]
  - If the recipient has never received a COVID-19 vaccine, administer 1 dose of Moderna COVID-19 Vaccine.
- Children with a history of myocarditis or pericarditis:
  - If history is prior to COVID-19 vaccination, may receive Moderna vaccine product for 6 years through 11 years of age. After the episode of myocarditis or pericarditis has completely resolved.
  - If myocarditis or pericarditis occurred after the first dose of an mRNA vaccine, experts advise no additional doses of any COVID-19 vaccine, including Moderna product for children 6 through 11 years of age. Administration of the second dose of an mRNA COVID-19 vaccine series can be considered in certain circumstances after the episode of myocarditis or pericarditis has completely resolved. Considerations can be found at www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-Moderna-moderna
- Additional clinical considerations
  - For children who received a COVID-19 vaccine that is not currently authorized or approved in the United States, guidance can be found at: www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html#not-authorized-vaccines
  - Moderna COVID-19 Vaccine may be coadministered with other vaccines without regard to timing, including simultaneous administration.
  - For recommendations for COVID-19 vaccination and SARS-CoV-2 infection, see www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#CoV-19-vaccination

6 Months Through 5 Years of Age
Moderna COVID-19 Vaccine
Standing Orders for Administering Vaccine

Vaccine	Dosage (amount)/ Route
Formulation: 6 months through 5 years of age	0.25 mL/IM injection

Purpose

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure

Assess children 6 months through 5 years of age for vaccination with Moderna COVID-19 Vaccine based on the following criteria:

- Children who ARE NOT moderately or severely immunocompromised[1]
  - Primary Series
    - If the recipient has never received a COVID-19 vaccine, administer 1 dose of Moderna COVID-19 Vaccine.
    - If the recipient has received 1 previous dose of Moderna COVID-19 Vaccine, administer the second dose at least 4–8 weeks after Dose 1.
- Children who ARE moderately or severely immunocompromised[1]
  - Primary Series
    - If the recipient has never received a COVID-19 vaccine, administer 1 dose of Moderna COVID-19 Vaccine.
    - If the recipient has received 1 previous dose of Moderna COVID-19 Vaccine, administer the second dose at least 4
  - If myocarditis or pericarditis occurred after the first dose of an mRNA vaccine, experts advise no additional doses of any COVID-19 vaccine. If, after a risk assessment, a decision is made to administer a subsequent dose of COVID-19 vaccine, vaccine should not be administered until the myocarditis or pericarditis has resolved. Clinical considerations can be found at www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-pfizer-biontech-moderna
- Additional clinical considerations
  - For children who received a COVID-19 vaccine that is not currently authorized or approved in the United States, guidance can be found at: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html#not-authorized-vaccines
  - Moderna COVID-19 Vaccine may be coadministered with other vaccines without regard to timing, including simultaneous administration.
  - For recommendations for COVID-19 vaccination and SARS-CoV-2 infection, see https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#CoV-19-vaccination

Screen for contraindications and precautions

Contraindications:

History of:

- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine
- Known diagnosed allergy to a component of the vaccine (see https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#appendix-f)

Precaution:

Standing Order Links - Janssen

Link to Janssen

Janssen COVID-19 Vaccine (Johnson & Johnson)

Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older

Vaccine	Dosage (amount)/ Route
Janssen COVID-19 Vaccine (Johnson & Johnson)	**0.5 mL**/IM injection

Purpose

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure

Assess persons 18 years of age and older for vaccination with Janssen COVID-19 Vaccine based on the following criteria:

- If the recipient has never received a COVID-19 vaccine, administer 1 dose of Janssen COVID-19 vaccine.
- If the recipient has received 1 dose of a Janssen COVID-19 Vaccine, no additional primary-series doses are needed. A booster dose is recommended 2 months (8 weeks) after the primary Janssen dose; any FDA-authorized or approved COVID-19 vaccine may be given.
- If 2 doses of an mRNA vaccine or a single dose of Janssen COVID-19 Vaccine has been administered, the person is considered fully vaccinated 2 weeks after completing the primary vaccination series.
- In situations where the first dose of an mRNA COVID-19 vaccine was received but the patient is unable to complete the series with either the same or different mRNA COVID-19 vaccine, (e.g., due to contraindication) consideration may be given to vaccination with the Janssen COVID-19 Vaccine at a minimum interval of 28 days after receipt of mRNA COVID-19 vaccine dose. However, vaccination should be done in an appropriate setting under the supervision of a healthcare provider experienced in the management of severe allergic reactions. Consider referral to an allergist-immunologist.[1]
- Thrombocytopenia syndrome (TTS) and thrombocytopenia:
  - Inform women aged 18-49 years of the increased risk of thrombosis with thrombocytopenia syndrome (TTS) in their age group after Janssen COVID-19 vaccination and about the availability of other authorized vaccines (i.e., mRNA vaccines).
  - A second dose of Janssen COVID-19 vaccine is not recommended for people who had TTS after their first dose. These people may receive a dose of mRNA COVID-19 vaccine as a booster dose at least 2 months (8 weeks) after their dose of Janssen vaccine and after their clinical condition has stabilized.[1]
    - A consultation with the patient's clinical team, including hematologists or other specialists, should be considered.
  - Offer another FDA-authorized or approved vaccine (i.e., mRNA vaccine) to unvaccinated persons with a history of an episode of an immune-mediated syndrome characterized by thrombosis and thrombocytopenia (e.g., heparin-induced thrombocytopenia) if it has been 90 days or less since their illness resolved. After 90 days, patients may be vaccinated with any FDA-authorized or approved COVID-19 vaccine.

NOTE: Persons at risk or with a history of other thrombosis not associated with thrombocytopenia can receive an FDA-authorized or approved vaccine

- People with a history of Guillain-Barré Syndrome (GBS):
  - Can receive any FDA-authorized or approved COVID-19 vaccine. However, given the possible association between the Janssen COVID-19 Vaccine and an increased risk of GBS, discuss with these patients the availability of mRNA COVID-19 vaccines that offer protection against COVID-19.
- Persons who have received HCT or CAR-T-cell therapy
  - Revaccinate persons who received doses of COVID-19 vaccine prior to receiving HCT or CAR-T-cell therapy with a primary series at least 3 months (12 weeks) after transplant or CAR-T-cell therapy.
- Booster doses:
  - Administer a booster dose at least 2 months (8 weeks) after completion of the Janssen COVID-19 Vaccine primary dose to:

Standing Order Links - Novavax

Link to Novavax

Novavax COVID-19 Vaccine

Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older

Vaccine Product	Dose/Injection Amount	Route
Blue capped vial	5 µg rS and 50 µg of Matrix-M™ adjuvant/0.5 mL	Intramuscular (IM) injection

Purpose

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure

Assess persons 18 years of age and older for vaccination with Novavax COVID-19 Vaccine based on the following criteria:

Persons who **are NOT** moderately or severely immunocompromised[†]

- If the recipient has never received a COVID-19 vaccine, administer 1 dose of Novavax COVID-19 Vaccine.
- If the recipient has received 1 previous dose of:
  - Novavax COVID-19 Vaccine, administer the second dose at least 3 to 8 weeks after the first dose.
  - A vaccine product that cannot be determined, is no longer available or contraindicated, administer Novavax COVID-19 Vaccine at least 4-8 weeks after the first dose.

Persons who **ARE** moderately or severely immunocompromised[†]

- If the recipient has never received a COVID-19 vaccine, administer 1 dose of Novavax COVID-19 Vaccine.
- If the recipient has received 1 previous dose of
  - Novavax COVID-19 Vaccine, administer the second dose at least 3 weeks after Dose 1.
  - A vaccine product that cannot be determined, is no longer available or contraindicated, administer Novavax COVID-19 Vaccine at least 4 weeks after the first dose.

- Persons with a history of myocarditis or pericarditis:
  - If history is prior to COVID-19 vaccination, may receive Novavax COVID-19 Vaccine, after the episode of myocarditis or pericarditis has completely resolved.
  - If myocarditis or pericarditis occurred after the first dose of an mRNA or Novavax COVID-19 vaccine, generally experts advise no additional doses of any COVID-19 vaccine. Administration of the second dose of an mRNA or Novavax COVID-19 vaccine series can be considered in certain circumstances after the episode of myocarditis or pericarditis has completely resolved. Considerations can be found at https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#myocarditis-pericarditis
- Additional clinical considerations
  - For people who received a COVID-19 vaccine outside the United States, guidance can be found at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a
  - Novavax COVID-19 Vaccine may be coadministered with other routinely recommended vaccines without regard to timing, including simultaneous administration.
  - For recommendations for COVID-19 vaccination and SARS-CoV-2 infection, see https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#infection
- Persons who have received HCT or CAR-T-cell therapy
  - Revaccinate persons who received doses of COVID-19 vaccine prior to or during receiving HCT or CAR-T-cell therapy with a primary series at least 3 months (12 weeks) after transplant or CAR-T-cell therapy.
- Screen for contraindications and precautions.
  - **Contraindications**
    - History of a:
      - Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine
      - Known diagnosed allergy to a component of the vaccine (see https://www.cdc.gov/vaccines/covid-19/clinical-

ADHS Vaccine Reference Sheets - Janssen

Janssen (Ages 18+)

- Janssen Vaccine Reference Sheet
- What Patients and Providers Need to Know About the Janssen Vaccine

Vaccine Storage

Janssen COVID-19 Vaccine

Refrigerator

- 2.0° C to 8.0° C
- 36.0° F to 46.0° F
- Store in refrigerator for up to 11 months
- DO NOT REFREEZE

Dosage

- Each vaccine vial contains 5, 0.5mL doses to be administered
- No reconstitution required
- Discard any punctured vial held at refrigerator temperatures after 6 hours
- Discard any punctured vial held at room temperature (maximally 25°C/77°F) after 2 hours

Administration

- Standard needles and syringes
- Draw 0.5mL and inject intramuscularly (IM)
- Single dose
- For adults 18 and older
- Not for children
- Can be administered until 11:59 p.m. EST on expiry date. Expiry dates can be verified on the Janssen website

The storage and handling information found on the Fact Sheet supersedes the storage and handling information on the carton and vial labels.

ARIZONA DEPARTMENT OF HEALTH SERVICES
PREPAREDNESS

Disclaimer: Subject to change due to FDA EUA approval
UPDATED 4/12/22

Vaccine Manufacturer COVID-19 Websites

- Comirnaty/Pfizer COVID-19 Website
- Moderna COVID-19 Website
- Janssen COVID-19 Website
- Novavax COVID-19 Website

Pfizer-BioNTech COVID-19 Vaccine

Pfizer BIONTECH English

Global Information About Pfizer-BioNTech COVID-19 Vaccine (also known as BNT162b2)

The approval status of the Pfizer-BioNTech COVID-19 Vaccine varies worldwide. In countries where the vaccine has not been approved by the relevant regulatory authority, it is an investigational drug, and its safety and efficacy have not been established.

As country information may vary, please choose the country below in which you are a licensed healthcare professional for more information on the Pfizer-BioNTech COVID-19 Vaccine.

This site is intended for Healthcare Professionals only.

I am a Healthcare Professional in:

Select

I am **NOT** a Healthcare Professional

Select

Report an Adverse Event

Information about the Pfizer-BioNTech COVID-19 Vaccine is only available for certain countries. This site will be updated as more information becomes available.

Moderna COVID-19 Vaccine

moderna

GO TO FULL UNITED STATES SITE H

For US Vaccination Providers ▶

For US V

- The Moderna COVID-19 Vaccine has not been approved or licensed by the U Administration (FDA), but has been authorized for emergency use by FDA, u Authorization (EUA), to prevent Coronavirus Disease 2019 (COVID-19) for u age and older. There is no FDA-approved vaccine to prevent COVID-19.
- The EUA for the Moderna COVID-19 Vaccine is in effect for the duration of t declaration justifying emergency use of the product, unless the declaration is authorization is revoked sooner.

Download EUA Fact Sheet & Full PI for **Vaccination Providers**

Download EUA Fact Sheet for **Vaccine Recipients** & Caregivers

Look Up Vaccine Expiration Dates For **Vaccination Providers**

novavax | Novavax COVID-19 Vaccine (recombinant, adjuvanted)

Global information about the Novavax COVID-19 Vaccine (recombinant, adjuvanted)

The approval status of the Novavax COVID-19 Vaccine (recombinant, adjuvanted) (also known as NVX-CoV2373) varies worldwide. In countries where the vaccine has not been approved by the relevant regulatory authority or regulatory process, you will not find information about it on this site. This site will be updated as more information becomes available.

janssen | Johnson & Johnson

Important Safety Information Janssen.com Contact Us

The U.S. FDA Has Granted the Janssen COVID-19 Vaccine an Emergency Use Authorization (EUA)

To learn more, choose the appropriate option:

I am a healthcare provider

I am NOT a healthcare provider

The Janssen COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized by FDA through an Emergency Use Authorization (EUA) for active immunization to prevent Coronavirus Disease 2019 (COVID-19) in individuals 18 years of age and older. The emergency use of this product is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the medical product under Section 564(b)(1) of the FD&C Act, unless the declaration is terminated or authorization revoked sooner.

FD&C Act=Federal Food, Drug, and Cosmetic Act

IMPORTANT SAFETY INFORMATION +

CONTRAINDICATIONS

Do not administer the Janssen COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Janssen COVID-19 Vaccine.

WARNINGS AND PRECAUTIONS

- **Management of Acute Allergic Reactions:** Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Janssen COVID-19 Vaccine.

CDC COVID-19 Vaccine Resources

- [CDC Pfizer (Comirnaty) Resource Page]
- [CDC Moderna Resource Page]
- [CDC Janssen Resource Page]
- [CDC Novavax Resource Page]

Novavax COVID-19 Vaccine
Vaccine Preparation and Administration Summary

General Information

Janssen COVID-19 Vaccine (Johnson & Johnson)
Vaccine Preparation and Administration Summary

General Information
Vaccine: Janssen COVID-19 Vaccine (Johnson & Johnson)

Administration
Intramuscular (IM) injection in the deltoid muscle

Moderna COVID-19 Vaccine
Vaccine Preparation and Administration Summary

12 Years of Age and Older
Pfizer-BioNTech COVID-19 Vaccine
Vaccine Preparation and Administration Summary

General Information
Vaccine: Pfizer-BioNTech,12 years of age and older (purple cap)
Use the correct formulation based on the age of the recipient
Diluent: 1.8 mL of 0.9% sodium chloride (normal saline, preservative-free) Use a new vial every time.
Multidose vial: 6 doses per vial
Dosage: 0.3 mL.
Prepare the vaccine using a NEW vial of diluent EVERYTIME. Discard the diluent vial and remaining diluent after mixing the vaccine.

Age Indications
12 years of age and older

Thawing Frozen Vaccine
- Frozen vaccine must be thawed before using.
- Thaw vaccine in the refrigerator or at room temperature:
  - **Refrigerator:** Between 2°C and 8°C (36°F and 46°F) Unpunctured vials may be stored in the refrigerator for up to 1 month (31 days).
  - **Room temperature (for immediate use):** Up to 25°C (77°F) Unpunctured vials cannot be kept at room temperature for more than 2 hours (including thaw time).
- Amount of time needed to thaw vaccine varies based on temperature and number of vials.

- **Do NOT** refreeze thawed vaccine.
- Use vials in the refrigerator before removing vials from ultra-cold temperature or freezer storage.
- Use CDC's beyond-use date labels for this vaccine to track storage time at refrigerated and frozen temperatures.

Schedule for Primary Series and Booster Dose
- 2-dose series separated by 21 days*
- Moderately and severely immunocompromised people: Administer an additional Pfizer-BioNTech dose at least 28 days after the initial 2-dose primary series.*
- A primary series started with Pfizer-BioNTech COVID-19 Vaccine should be completed with this product.
- A booster dose, at least 6 calendar months after the last dose of a COVID-19 mRNA primary series[1] (i.e., after the 2nd dose or after the additional [3rd] dose for moderately or severely immunocompromised persons)
  - Should be given to persons 18 years of age and older (Use of heterologous- mix and match - booster doses is allowed)
  - May be given to persons 16 and 17 years of age based on their individual benefits and risks

Administration
Intramuscular (IM) injection in the deltoid muscle

Prepare the Vaccine

Follow aseptic technique. Perform hand hygiene before vaccine preparation, between patients, when changing gloves (if worn), and any time hands become soiled.[2]

Remove vaccine from the storage unit. **Check the vial label to ensure it is the correct formulation based on the age of the recipient. The vial for persons 12 years of age and older has a purple cap and purple border on the label.** Allow vaccine to come to room temperature. Vials can be held at room temperature for up to 2 hours before mixing.

Before mixing, check the:
- expiration date on the vaccine and diluent
- any beyond-use dates/times

NEVER use expired vaccine or diluent. **NEVER** use vaccine after the beyond-use date or times.

With the vaccine at room temperature, gently invert vial 10 times. **Do not shake the vial.** If the vial is shaken, contact the manufacturer. The vaccine is white to off-white in color and may contain opaque particles. Do not use if liquid is discolored.

Using a new, sterile alcohol prep pad for each vial, wipe off the stoppers of the diluent and vaccine vials. Using a 21-gauge (or narrower) needle, **withdraw 1.8 mL** of 0.9% sodium chloride (normal saline, preservative-free) into a mixing syringe. Discard diluent vial and any remaining diluent every time. **Do NOT** use bacteriostatic normal saline or other diluents to mix the vaccine.

* For more information, please see Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States at https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

COVID-19 Vaccine Expiration Dates - Pfizer

Pediatric Pfizer Maroon Cap Monovalent and Bivalent (Ages 6 months - 4 years)

- Date printed on vial and tray is **manufacturing date only**
- Use the Pfizer website

Base expiration date on storage method and manufacturing date. For example:

- If the manufacturer date is 8/2021 and the doses are stored in an ultra-low-temp freezer, the doses would expire April 30, 2022.
- If the doses are put in the refrigerator November 2, 2021, they would expire 10 weeks from November 2 on January 11, 2022.

Pfizer Orange Cap (Ages 5-11)

- Date printed on vial and tray is **manufacturing date only**
- Use the Pfizer Age 5-11 EUA Fact Sheet (Page 3)
- Use the Pfizer website

Base expiration date on storage method and manufacturing date. For example:

- If the manufacturer date is 8/2021 and the doses are stored in an ultra-low-temp freezer, the doses would expire April 30, 2022.
- If the doses are put in the refrigerator November 2, 2021, they would expire 10 weeks from November 2 on January 11, 2022.

Pfizer Gray Cap (Ages 12+)

- Date printed on vial and tray is **manufacturing date only**
- Use the Pfizer Gray Cap (Ages 12+) EUA Fact Sheet (Page 5)
- Use the Pfizer website

Base expiration date on storage method and manufacturing date. For example:

- If the manufacturer date is 8/2021 and the doses are stored in an ultra-low-temp freezer, the doses would expire April 30, 2022.
- If the doses are put in the refrigerator November 2, 2021, they would expire 10 weeks from November 2 on January 11, 2022.

Comirnaty Gray Cap (Ages 12+)

- Date printed on vial and tray is the **expiration date**
- Use the Pfizer website to double check expiration dates

Pfizer-BioNTech Bivalent Booster (Ages 12+, No Diluent) - Gray Cap

- Date printed on vial and tray is the **expiration date**
- Use the Pfizer website to double check expiration dates

Pediatric Pfizer-BioNTech Bivalent Booster (Ages 5 - 11 years) - Orange Cap

- Date printed on vial and tray is the **expiration date**
- Use the Pfizer website to double check expiration dates

COVID-19 Vaccine Expiration Dates - Moderna, Novavax and Janssen

Pediatric Moderna Blue Cap with Magenta Border on label (Ages 6 months to 5 years)

- Use QR code
- Enter lot number on expiration date checker website

Pediatric Moderna Blue Cap with Purple Border on label (Ages 6 to 11 years)

- Use QR code
- Enter lot number on expiration date checker website

Moderna Bivalent Booster Dark Pink Cap with Yellow Border on label (Ages 6 months - 5 years)

- Use QR code
- Enter lot number on expiration date checker website

Moderna Bivalent Booster Blue Cap (Ages 6+)

- Use QR code
- Enter lot number on expiration date checker website

Moderna Red Cap (Ages 12+)

- Use QR code
- Enter lot number on expiration date checker website

Janssen

- Use QR code
- Enter lot number on expiration date checker website
- Can be used until 11:59 EST on expiry date

Novavax

- Use QR code
- Enter lot number on expiration date checker website

CDC Expiration Date Tracking Tool

- Pfizer Gray Cap (ages 12+) , Orange Cap (ages 5-11yrs) & Maroon Cap (ages 6mo - 4yrs) doses can be refrigerated for up to 10 weeks
- Moderna doses can be refrigerated for up to 30 days
- Janssen doses can be refrigerated for up to 11 months
- Providers should check the latest expiry information on the manufacturer's website before doses are removed from the unit

COVID-19 Vaccine Expiration Date Tracking Tool

Use this tracking tool to record updated expiration dates for COVID-19 vaccine as additional stability data are available from the manufacturer. When the current expiration date gets close, contact the manufacturer before discarding vaccine. Document the current date, the vaccine lot number, and the updated expiration date in the appropriate columns, including the information source and the name of the person completing this form. Keep this document for 3 years or longer if required by your jurisdiction..

Product name: _____ **Manufacturer:** _____ **Original Expiration Date:** _____

Expiration date info is available at (include all available information from manufacturer; website, app, phone number.)

Date	Lot Number	Updated Expiration Date	Info Source	Name
Example: 09/01/2020	*ABC123DEF456*	*06/30/2021*	☒ Website ☐ Barcode	*Susie Smith RN*

COVID-19 Vaccine and Beyond-use Dates (BUDs)

- CDC has developed tracking labels refrigerators and freezers to help monitor and document cold storage dates
- Assist with documenting transportation time and temperature
- Available for both Moderna and Pfizer/Comirnaty vaccines
- Moderna COVID-19 Vaccine: Beyond Use Date/Time (BUD) Tracking Label for Vaccine During Refrigerator Storage (cdc.gov)
- Pfizer-BioNTech COVID-19 Beyond Use Date/Time (BUD) Tracking Labels for Vaccine During Freezer or Refrigerator Storage (cdc.gov)

Returning Thermal Shipping Containers (Once Empty)

Pfizer

- Shippers **DO NOT** need to be returned
- Only controlant data logger needs to be returned

Moderna

- Return using the return label located on the inside of the box

Janssen (Ages 18+)

- Shippers do not need to be returned

Novavax (Ages 18+)

- Shippers do not need to be returned

Vaccine Process

Vaccines are widely available

- Providers enter their COVID-19 vaccine order in ASIIS
- BIZS will approve the order
- The order goes to CDC to Distributor/Manufacturer
- The order is shipped (will show in ASIIS)
- Provider receives shipment of ancillary kit and vaccine (may not be same day)
- Provider logs into ASIIS to mark doses as “received”
- Provider administers vaccine
- Provider reports the administered vaccine to ASIIS through their EHR, State VMS POD application, directly in ASIIS or using Mass Immunization Module in ASIIS
- The dose is subtracted from the ASIIS inventory if properly recorded in a patient’s ASIIS record

ASIIS Information

Placing Orders in ASIIS

- Providers who have an approved onboarding submission are able to order vaccines
- AIPO Train courses
  - How to Place an Order in ASIIS
  - Vaccine Inventory Management - information on ordering and inventory reconciliation
  - Sign up for Dose Accountability Webinar
    - Recordings available any time within AIPO Train course
  - Included in Pandemic Provider course bundle
- Use COVID-19 Vaccine Presentations Job Aid to help make ordering decisions



Pfizer pediatric doses (5-11) should NOT be reported as adult doses

Reminder:

The CPT and CVX codes for the Pfizer age 5-11 vaccine and the Pfizer age 12+ vaccine are different.

Please ensure that your EHR has been updated to document the vaccines correctly.

For information on Arizona HL7 Specific Rules for Version 2.5.1, click here.

For information on List of Vaccine Names, Best ASIIS Selection and CPT/CVX Codes, click here.

List of Vaccine Names, Best ASIIS Selection and CPT/CVX Codes

ARIZONA DEPARTMENT OF HEALTH SERVICES

This list matches the vaccine name or codes in Arizona State Immunization Information System (ASIIS) with the brand name or other common names of the vaccines you use most often.

Vaccine trade name or common name	Fund	Best ASIIS Selection	Age (Range)	Dose	Route	Manufacturer/ NDC Number	CPT Code	CVX Code
COVID-19 Vaccines								
COMIRNATY Pfizer COVID-19 Vaccine	PAN	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose	16+ years 12+ years EUA	0.3 ml	IM	Pfizer, INC – PFR NDC: 59267-1000-02 (195pack-6dose vials) (1170 doses)	91300	208
	PAN	COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose	5-<12 years EUA	0.2 ml	IM	Pfizer, INC – PFR NDC: 59267-1055-04 (10pack-10dose vials) (100 doses)	91307	218
Moderna COVID-19 Vaccine	PAN	COVID-19, mRNA, LNP-S, PF,	18+ years	0.5 ml	IM	Moderna – MOD NDC: 80777-0273-99 (10pack-10dose vials) (100 doses)	91301	207
Janssen COVID							91303	212
AstraZeneca COVID-							91302	210
Novavax COVID-19								211
Sinopharm (BIBP) C								510
Coronavac (Sinovac								511
SARS-COV-2 (COVID								213

Arizona HL7 Specific Rules for Version 2.5.1

The following specifications and rules supersede CDC and general HL7 guidelines when sending messages to the Arizona Immunization Program. Otherwise CDC and general HL7 guidelines apply.

MSH.1 – **Field Separator** will be the pipe **|** identified as (ASCII 24)

MSH.2 – **Encoding Characters** will be **^~\&** identified as (ASCII 94, ASCII 126, ASCII 92, ASCII 38) respectively.

MSH.3 – **Sending Application** is **required**

MSH.4 – **Sending Facility** is **required** and shall be the **IRMS ID** assigned and provided by the ASIIS System.

MSH.5 – **Receiving Application** is **required** and shall always be **ASIIS**.

MSH.6 – **Receiving Facility** is **required** and shall always be **ASIIS**.

MSH.7 – **Date/Time of Message** is **required** and shall be in the following format (**YYYYMMDDHHMMSS**) and have a degree of precision to the minute generated.

MSH.9 – **Message Type** is **required** and shall be **VXU^V04^VXU_V04** for Unsolicited Vaccination Messages.

MSH.10 – **Message Control ID** is **required** and shall be unique for each message attempt from a sending facility with a maximum of 20 characters.

MSH.11 – **Processing ID** is **required** and because the ASIIS system has separate points for

Vaccine Transfer Process

- Both the sending and receiving providers will email data logger reports to ArizonaVFC@azdhs.gov
- Transfers must be approved in ASIIS prior to moving the doses
  - Enter the transfer in ASIIS prior to moving the doses
    - Information you will need for ASIIS
      1. The organization and facility sending the doses
      2. The organization and facility receiving the doses
      3. The quantity
      4. The lot number
  - When the doses arrive, mark them "received" in ASIIS. Do not administer doses before "receiving" them in the ASIIS inventory
- **Only onboarded, active COVID-19 vaccine providers may receive COVID-19 vaccines**
- Follow the USP transfer guidelines when packing the doses for transfer
  - Once frozen doses have been thawed they cannot go back into a freezer
- Wherever the vaccines are, data loggers must be with them to monitor the temperatures
- The ancillary kit must also be transferred with the doses

Vaccine Wastage

- **If vaccine expires before you can use it:**
  1. Follow the instructions on this job aid to process wastage in ASIIS. Please note that COVID vaccines will not need to be returned
  2. Dispose of the vaccine
- Expired/wasted COVID-19 doses should be disposed of in a sharps container or per the hazardous waste policy in your office
- Tear off the vial labels or mark the identifying information (lot number, NDC number, etc) with a black marker prior to disposing
- Expired/wasted COVID-19 vaccines **DO NOT** go back to McKesson or Pfizer at this time
- How to Account for Wasted/Expired Doses Job Aid

Correcting Negative Doses in ASIIS

Reconciling ASIIS inventory

- Giving more doses than what is in the ASIIS inventory will make the inventory
- negative, which will mean you cannot submit inventory reconciliation
- Only if extracting extra doses from a vial
    - Ex. Extracting 15 doses from Moderna 14-dose vial
- AIPO Train module: Correcting Negative COVID-19 Doses in ASIIS

How to Run Reminder/Recall Report

- ASIIS Reminder/Recall Reports AIPO Train course
- Identify patients due/past due for vaccines
- Schedule patients
- Create letters, postcards, and mailing labels

If your ASIIS Inventory is not accurate

- Doses that have been administered to patients should not be removed from the Reconciliation page (Inventory) in ASIIS
- Troubleshoot why the doses did not decrement
  - Register for Dose Accountability Webinar in AIPO Train
  - Past Dose Accountability Webinar videos in course module
- Job aid to walk you through process of searching/adding/editing patient records manually in ASIIS

Mark doses as *Received* in VOMS 2.0 when the doses arrive

- Required regardless what system you use to document vaccine administration (EHR, VMS, ASIIS)
- When the doses arrive, mark them as ***Received*** in VOMS 2.0
  - Log into ASIIS
  - Go to Inventory Management> VOMS 2.0> Orders & Transfers > Click Receive button under Action header for the Inbound Order/Transfer
  - Verify the expiration date, lot number, and quantity of doses
  - Click the ***Receive*** button to receive the doses into the ASIIS Inventory
- After the doses are ***Received*** in VOMS 2.0, you may administer them
- If you administer doses before they are ***Received*** into the ASIIS inventory, they will not decrement from the ASIIS inventory



Funding Source - PAN

- The funding source should be PAN.
- If you have an EHR, your EHR vendor should send the code VXC50. On the user interface side, you will select PAN when administering.
- If you select VFC, State, Private, or something else as the funding source, the doses will not decrement from the ASIIS inventory.

Communication Resources

Granicus Communications (Email Updates)

The BIZS sends granicus updates (email updates) on a variety of topics including COVID-19 vaccines, ASIIS, routine vaccines, etc. This library can be accessed at any time with the above link to view previously sent updates.

Ad Council COVID-19 Vaccination Campaign: It's Up to You

getvaccineanswers.org

- Campaign site for consumers
- Answers common questions
- Provides vaccine information
- Link to Spanish site - www.DeTiDepende.org
- Creative materials that can be shared/used by providers



COVID-19 Vaccine Confidence Toolkit for Rural Jurisdictions

- Print ads
- Posters
- Brochure
- Social media posts
- Online resource guide
- PDFs can be customized using Adobe Acrobat Pro



ADHS COVID-19 Communication Resources

- Posters in English and Spanish (sample here)
- Addressing Misinformation (here)
- Answering Patient Questions (here)
- What to Expect After Getting COVID Vaccine (here)
- What to Expect at Your Vaccine Appointment (here)
- Vaccination Quick Answers (here)
- Answering Common Patient Questions (here)

COVID-19 Vaccine - Providers' Toolkit

- Order Form to request materials for your facility

HHS Video “Tell Me More About Vaccines”

The video answers commonly asked questions about the COVID-19 vaccine. The video shares why vaccines are so important and provides expert commentary and graphic illustration to help viewers understand the science of vaccine development. Tune in to hear from various experts, including Dr. Anthony Fauci (NIH), Dr. Stephen Hahn (FDA), and Dr. Robert Kadlec (ASPR), on the steps researchers and scientists are taking to develop a safe and effective vaccine. You are encouraged to add the video link to your website or promote it on social media.



FDA Emergency Use Authorization for Vaccines Explained

- What is an Emergency Use Authorization?
- Are the COVID-19 vaccines rigorously tested?
- What safety and effectiveness data are required to be submitted to FDA for an EUA request for a vaccine intended to prevent COVID-19?

CDC COVID-19 Vaccination Communication Toolkits

- For Medical Centers, Clinics, Pharmacies, and Clinicians
- For Healthcare Professionals and Pharmacists
- For LTCF Administrators and Leadership
- For Employers of Essential Workers
- For Staff of Organizations Serving Communities
- Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit

The toolkit contains a variety of resources that you can use virtually or in person (with proper COVID-19 safety precautions):

- Posters
- FAQ
- Key messages
- Slide decks

Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit

Updated May 15, 2021 Print

As parents' most trusted source of information on vaccines, pediatric healthcare professionals play a critical role in helping parents/guardians understand the importance of COVID-19 vaccination and assuring them that COVID-19 vaccines are safe and effective.

Your strong recommendation is critical for vaccine acceptance. Tell parents/guardians how important COVID-19 vaccines are to protecting their children's health.

Remind parents that after their family is fully vaccinated against COVID-19, they may start to do some things they had stopped doing because of the pandemic.

Even if you are not administering COVID-19 vaccines, you can help parents/guardians feel confident in choosing to get their children vaccinated against COVID-19 by addressing their questions and assuring them of the safety and effectiveness of COVID-19 vaccines.

The materials on this page will help you share clear and accurate information about COVID-19 vaccines when starting or continuing conversations with parents/guardians, as well as information for those who choose not to vaccinate their child.

Only healthcare professionals enrolled as vaccination providers directly through a health practice or organization can legally store, handle, and administer COVID-19 vaccine in the United States. Learn more about becoming a COVID-19 Vaccination Provider: How to Enroll as a COVID-19 Vaccination Provider.

COVID-19 Vaccination of Minors

Patients, parents, and guardians may have questions about consent for vaccination for minors recommended to receive a COVID-19 vaccine. Learn more at: Pfizer-BioNTech COVID-19 Vaccine.

Provider Resources for Patient Conversations About COVID-19 Vaccines

- How to talk to your patients about COVID-19 vaccination

CDC's Key Points to Communicate to Your Patients:

- COVID-19 vaccines are safe and effective.
- Individuals 12 and up are all eligible to get a COVID-19 vaccination.
- There are many locations to find a COVID-19 vaccine.
- Having some side effects after vaccination is normal.
- You are not fully vaccinated until 2 weeks after the 2nd dose of a two-dose vaccine or 2 weeks after a one-dose vaccine.

Recipient Education

Talking to Recipients about COVID-19 Vaccines

Many people have questions about the new coronavirus disease 2019 (COVID-19) vaccines. As vaccine recipients' most-trusted source of information on vaccines, you play a critical role in helping them understand the importance of COVID-19 vaccination, as well as if and when it is likely to be recommended for them.

The materials below include proven communication strategies and tips for effectively setting expectations and addressing questions from COVID-19 vaccine recipients.

Making a Strong Recommendation for COVID-19 Vaccination

Answering Vaccine Recipients' Questions

Understanding and Explaining COVID-19 Vaccines

Background and safety information for healthcare professionals and other vaccine providers, as well as tips for explaining the vaccines to patients.

- mRNA COVID-19 Vaccines
- Viral Vector COVID-19 Vaccines

CDC COVID-19 Vaccine Web Pages for the general public

- Benefits of Getting a COVID-19 Vaccine
- How COVID-19 Vaccines Work
- Frequently Asked Questions about COVID-19 Vaccination
- Understanding MRNA vaccines
- What to Expect at Your Appointment to Get Vaccinated for COVID-19
  - Translated in many languages
- When You've Been Fully Vaccinated
- Webpage COVID-19 Vaccines for Children and Teens



FAQs

FAQs

Q: If I am a VFC provider and already have an ASIIS PIN, do I still need to onboard?

- A: Yes. If a facility location wants to administer COVID-19 vaccines, they will need to onboard and sign the CDC COVID-19 Agreement. The VFC Program and the COVID-19 vaccine program are separate programs with separate signed Agreements.

Q: How do I order COVID-19 vaccines in ASIIS?

- A: Onboarded and active COVID-19 providers can follow the instructions in this job aid on how to place orders

Q: Where can I find these slides?

- A: These slides can be found at azdhs.gov/covid19vaccine on the Provider Resources page. You can also find a link to the slides and the most recent recording in the Pandemic Provider Weekly Brown Bag course in AIPO Train.

THANK YOU!